Throughout my career, I have had the opportunity to work in both academic science and biotechnology, and that experience has shaped how I think about innovation. Academia is an extraordinary environment for asking fundamental questions and expanding our understanding of biology. Biotechnology provides another perspective. It asks how that knowledge can be developed into something that addresses a real medical need.
The transition between these worlds is not always simple. A scientific discovery can be fascinating and potentially important without necessarily becoming a useful therapy. Moving from an interesting finding to a medical solution requires a different set of questions. What problem are we trying to solve? Can the science be developed into a reliable therapeutic approach? What will it take to manufacture, test, and eventually deliver it to patients?
This is where entrepreneurial thinking can add significant value. It does not replace scientific rigor. Instead, it provides a framework for turning scientific potential into practical outcomes.
Starting With the Problem
One of the most useful lessons from entrepreneurship is the importance of starting with a clear problem. In science, it can be tempting to become excited about a technology simply because it is new or technically impressive. However, the most valuable innovations usually begin with an important unmet need.
In medicine, that means understanding the disease and the limitations of current treatments. If patients continue to experience poor outcomes, significant side effects, or limited treatment options, there may be an opportunity for a fundamentally different approach.
Starting with the problem also helps researchers determine which scientific questions matter most. Instead of asking whether a technology can do something, we can ask whether what it can do has the potential to make a meaningful difference.
That distinction can help focus research and prevent teams from pursuing interesting ideas that have limited practical value.
Thinking Beyond the Laboratory
Academic research often focuses deeply on a specific scientific question. That depth is essential, but therapeutic development requires looking at the entire journey from discovery to patient.
Entrepreneurial thinking encourages researchers to consider what happens after the initial discovery. Can the technology be scaled? Can it be manufactured consistently? Will it be safe? Can it be delivered effectively? Is there a realistic path through clinical development and regulatory review?
These questions should not replace scientific exploration. They should complement it.
When researchers consider these issues early, they may identify opportunities to improve a technology before significant resources are invested. They may also recognize technical limitations that need to be addressed before a program can progress.
Taking Calculated Risks
Entrepreneurship involves risk, and so does scientific research. The difference is that successful entrepreneurs try to understand and manage risk rather than simply avoid it.
In biotechnology, there is no way to eliminate uncertainty. New therapies involve biological questions that may not have clear answers. Clinical development can produce unexpected results, and manufacturing challenges can emerge as programs scale.
The key is determining which risks are worth taking and how they can be tested. A good development strategy creates opportunities to learn before making larger commitments.
This mindset can help scientific organizations move forward without being reckless. It encourages teams to make decisions based on evidence while recognizing that uncertainty is unavoidable.
Creating a Bridge Between Science and Business
Scientists and business professionals sometimes approach problems from very different perspectives. Scientists may focus on mechanisms, data, and experimental results, while business leaders may focus on resources, timelines, markets, and strategy.
Entrepreneurial thinking can help connect these perspectives. A successful biotechnology company needs both.
Scientific quality is the foundation of any therapeutic program, but resources are limited. Companies must decide which programs to advance, which experiments to prioritize, and when to change direction.
Understanding the commercial and operational realities of development does not diminish the science. It helps ensure that strong science has the resources and strategy necessary to reach patients.
Building Teams Around Innovation
Entrepreneurial thinking also changes how we build teams. Innovation rarely comes from one discipline working alone. Developing a new therapy may require immunologists, molecular biologists, engineers, clinicians, regulatory experts, manufacturing specialists, and business leaders.
The goal is not simply to assemble talented individuals. It is to create a team where those individuals can combine their strengths.
Entrepreneurial leaders need to create environments where people can question assumptions, share ideas, and take ownership. They also need to make sure everyone understands the larger mission.
When teams are aligned around a meaningful problem, collaboration becomes much more productive.
Learning From Setbacks
One of the most important entrepreneurial lessons is that setbacks are part of the process. In biotechnology, experiments fail, programs change direction, and promising ideas sometimes do not translate into clinical benefit.
The response to these setbacks is important. A culture that treats every failure as a personal mistake can discourage innovation. A culture that treats setbacks as data can help organizations learn faster.
This does not mean ignoring failure or lowering standards. It means asking what the result tells us and whether it changes our understanding of the problem.
Sometimes a failed experiment eliminates an approach that would otherwise have consumed significant resources. In that sense, learning what does not work can be extremely valuable.
Keeping the Patient at the Center
Entrepreneurial thinking is sometimes associated with growth and commercial success, but in biotechnology the ultimate measure of success should be patient impact.
A company can develop an impressive technology platform, attract significant investment, and achieve important scientific milestones. Those achievements matter, but they are not the final objective.
The real question is whether the work can eventually improve the lives of patients.
Keeping this perspective helps organizations make better choices. It encourages teams to focus on meaningful medical problems and develop technologies that have a realistic path toward clinical use.
Creating a Culture That Moves Ideas Forward
Turning scientific discovery into a medical solution requires a culture that supports both curiosity and action. Researchers need the freedom to explore new ideas, but they also need clear priorities and a willingness to make decisions.
Entrepreneurial thinking creates this balance. It encourages people to ask what comes next, how a discovery can be developed, and what obstacles need to be overcome.
The best biotechnology organizations combine the intellectual freedom of science with the focus and urgency of entrepreneurship.
Looking Toward the Future
The opportunities ahead in biotechnology are extraordinary. Advances in cell therapy, immunology, regenerative medicine, genetic engineering, and other areas are creating possibilities that were difficult to imagine only a generation ago.
The challenge is turning those possibilities into practical therapies. That will require scientists who are willing to think beyond the laboratory and entrepreneurs who understand the importance of scientific rigor.
The two perspectives are not competing. They are complementary.
Closing Thoughts
Scientific discovery gives us new knowledge, but entrepreneurial thinking helps us determine how that knowledge can create real-world value. It encourages us to start with important problems, manage uncertainty, build diverse teams, and consider the entire path from laboratory research to patient care.
My experience moving between academia and biotechnology has reinforced my belief that the most meaningful innovation occurs when these perspectives come together. Great science needs curiosity and rigor, but it also needs vision, strategy, and execution.
When we combine those qualities, scientific discoveries have a much better chance of becoming medical solutions that genuinely improve people’s lives.